- $37.37bn
- $44.82bn
- $106.37bn
- 47
- 67
- 57
- 57
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | 16.36 | ||
PEG Ratio (f) | 3.77 | ||
EPS Growth (f) | 4.53% | ||
Dividend Yield (f) | 1.25% |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 2.24 | ||
Price to Tang. Book | 6.87 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 0.33 | ||
EV to EBITDA | 10.69 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 6.46% | ||
Return on Equity | 10.21% | ||
Operating Margin | 2.89% |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | 64,888 | 77,155 | 83,064 | 92,870 | 106,374 | 116,227.91 | 117,271.3 | 13.33% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | +17.14 | +25.98 | -7.11 | -3.05 | +2.31 | -30.54 | +23.59 | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Humana Inc. is a healthcare company. It operates through two segments: Insurance and CenterWell. The Insurance segment consists of Medicare benefits, marketed to individuals or directly through group Medicare accounts. It also includes its contract with the Centers for Medicare and Medicaid Services (CMS) to administer the Limited Income Newly Eligible Transition (LI-NET), a prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits. It also includes products consisting of employer group commercial fully insured medical and specialty health insurance benefits. The CenterWell segment includes pharmacy solutions, primary care, and home solutions operations. It also includes its strategic partnerships with Welsh, Carson, Anderson & Stowe (WCAS) to develop and operate senior-focused, payor-agnostic, primary care centers, as well as a minority ownership interest in Gentiva Hospice operations.
Directors
- Kurt Hilzinger NEC (61)
- Bruce Broussard PRE (58)
- Susan Diamond CFO (48)
- William Fleming CEX (53)
- Christopher Hunter CEX (52)
- Sue Schick CEX
- T. Alan Wheatley CEX (53)
- Cynthia Zipperle SVP (58)
- Nwando Olayiwola SVP
- Carolyn Tandy SVP
- Sam Deshpande CTO (56)
- Timothy Huval CAD (54)
- Vishal Agrawal OTH (46)
- Heather Cox OTH (50)
- William Shrank OTH (49)
- Joseph Ventura OTH (44)
- Frank Bisignano IND (61)
- Raquel Bono IND (64)
- Frank D'amelio IND (63)
- Wayne Frederick IND (49)
- John Garratt IND (52)
- David Jones IND (71)
- Karen Katz IND (64)
- Marcy Klevorn IND (61)
- William Mcdonald IND (64)
- Jorge Mesquita IND (59)
- James O'brien IND (66)
- Marissa Peterson IND (59)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- July 27th, 1964
- Public Since
- May 18th, 1971
- No. of Shareholders
- 637,767
- No. of Employees
- 67,600
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
- New York Stock Exchange
- Shares in Issue
- 120,401,661
- Address
- 500 W Main St, LOUISVILLE, 40202
- Web
- https://www.humana.com/
- Phone
- +1 5025801000
- Contact
- Lisa Stoner
- Auditors
- PricewaterhouseCoopers LLP
Latest News for HUM
Upcoming Events for HUM
Dividend For H1UM34.SA - 0.0752 BRL
Dividend For HUM.N - 0.8850 USD
Q3 2024 Humana Inc Earnings Release
Q3 2024 Humana Inc Earnings Call
Q4 2024 Humana Inc Earnings Release
Similar to HUM
Agilon Health
New York Stock Exchange
AMERICAN WELL
New York Stock Exchange
AMN Healthcare Services
New York Stock Exchange
Ardent Health Partners
New York Stock Exchange
Ati Physical Therapy
New York Stock Exchange
FAQ
As of Today at 21:11 UTC, shares in Humana are trading at $310.41. This share price information is delayed by 15 minutes.
Shares in Humana last closed at $310.41 and the price had moved by -37.17% over the past 365 days. In terms of relative price strength the Humana share price has underperformed the S&P500 Index by -52.4% over the past year.
The overall consensus recommendation for Humana is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Humana dividend yield is 1.14% based on the trailing twelve month period.
Last year, Humana paid a total dividend of $3.54, and it currently has a trailing dividend yield of 1.14%.Looking ahead, shares in Humana are due to go ex-dividend on 2024-09-30 and the next dividend pay date is 2024-10-25.
Humana are due to go ex-dividend on 2024-09-30 and the next dividend pay date is 2024-10-25. The historic dividend yield on Humana shares is currently 1.14%.
To buy shares in Humana you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $310.41, shares in Humana had a market capitalisation of $37.37bn.
Here are the trading details for Humana:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: HUM
Based on an overall assessment of its quality, value and momentum Humana is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Humana is $392.01. That is 26.29% above the last closing price of $310.41.
Analysts covering Humana currently have a consensus Earnings Per Share (EPS) forecast of $16.20 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Humana. Over the past six months, its share price has underperformed the S&P500 Index by -18.5%.
As of the last closing price of $310.41, shares in Humana were trading -15.78% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Humana PE ratio based on its reported earnings over the past 12 months is 16.36. The shares last closed at $310.41.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Humana's management team is headed by:
- Kurt Hilzinger - NEC
- Bruce Broussard - PRE
- Susan Diamond - CFO
- William Fleming - CEX
- Christopher Hunter - CEX
- Sue Schick - CEX
- T. Alan Wheatley - CEX
- Cynthia Zipperle - SVP
- Nwando Olayiwola - SVP
- Carolyn Tandy - SVP
- Sam Deshpande - CTO
- Timothy Huval - CAD
- Vishal Agrawal - OTH
- Heather Cox - OTH
- William Shrank - OTH
- Joseph Ventura - OTH
- Frank Bisignano - IND
- Raquel Bono - IND
- Frank D'amelio - IND
- Wayne Frederick - IND
- John Garratt - IND
- David Jones - IND
- Karen Katz - IND
- Marcy Klevorn - IND
- William Mcdonald - IND
- Jorge Mesquita - IND
- James O'brien - IND
- Marissa Peterson - IND